An analysis of 6-month follow-up efficacy of low-intensity extracorporeal shock wave therapy for refractory prostate-pelvic syndrome
10.3969/j.issn.1009-8291.2025.02.013
- VernacularTitle:低能量冲击波治疗难治性前列腺盆腔综合征6个月疗效分析
- Author:
Xiao XU
1
;
Guizhong LI
1
;
Xiang DAI
1
;
Jie WANG
1
Author Information
1. Department of Urology, Beijing Jishuitan Hospital Affiliated to Capital Medical University, Beijing 100096, China
- Publication Type:Journal Article
- Keywords:
low-intensity extracorporeal shock wave therapy;
prostate-pelvic syndrome;
chronic prostatitis;
chronic pelvic pain syndrome
- From:
Journal of Modern Urology
2025;30(2):157-160
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the long-term efficacy and safety of low-intensity extracorporeal shock wave therapy (Li-ESWT) for refractory prostate-pelvic syndrome (PPS). Methods: Clinical data of 173 patients with refractory PPS undergoing Li-ESWT at our hospital during Jan.2020 and Jan.2023 were retrospectively analyzed.All patients received weekly treatment for 8 consecutive weeks.Changes in the National Institutes of Health chronic prostatitis symptom index (NIH-CPSI)，international prostate symptom score (IPSS)，visual analog scale (VAS)，and international index of erectile function-5 (IIEF-5) were compared before treatment，immediately，1，3，and 6 months after treatment. Results: A total of 142 patients (82.1%) completed all follow-ups.Compared to baseline data，there was a statistically significant improvement in NIH-CPSI，IPSS，VAS，and IIEF-5 scores immediately after treatment and 1，3，and 6 months after treatment (P<0.01).No significant adverse reactions or complications were observed throughout the follow-up.At the time of treatment completion，115 patients (81.0%) had a decrease of ≥6 in NIH-CPSI; 99 patients (69.7%) had a decrease of ≥3 in IPSS; 121 patients (85.2%) had a decrease of ≥3 in VAS; 105 patients (73.9%) had an increase of ≥4 in IIEF-5.At the 6-month follow-up，patients who responded to treatment maintained satisfactory therapeutic effects. Conclusion: Li-ESWT can significantly improve clinical symptoms and quality of life for patients with refractory PPS，with therapeutic effects lasting at least 6 months.
